Fig. 6

a–t Recurrence-free interval (RFi) and benefits of tamoxifen in GEX signature quartiles (Q1–Q4). Kaplan–Meier plots for each quartile of selected GEX signatures stratified by treatment (Tam vs. control) in patients with ER+/HER2− tumors; a–d AR, e–h ESR1, i–l FOXA1, m–p Mast cells and q–t PGR. Hazard ratios (HRs) with 95% confidence intervals are shown for the full-time follow-up and the first 10 years. ER estrogen receptor, GEX gene expression, HER2 human epidermal growth factor receptor 2, HR hazard ratio, Q quartile, RFi recurrence-free interval, Tam tamoxifen